You are viewing a version of a model that has been updated. To access the latest version, and a more detailed display please go here.

DDMODEL00000090: Claret_2009_oncology_capecitabine_TGI

  public model
Short description:
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics Laurent Claret, Pascal Girard, Paulo M. Hoff, Eric Van Cutsem, Klaas P. Zuideveld, Karin Jorga, Jan Fagerberg, and Rene´ Bruno
PharmML (0.6.1)
  • Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the basis of Phase II Tumor Dynamics
  • L. Claret, P. Girard, P. M. Hoff, E. V. Cutsem, K. P. Zuideveld, K. Jorga, J. Fagerberg, R. Bruno
  • Journal of Clinical Oncology, 9/2009, Volume 27, pages: 4103-4108
  • Pharsight, Marseille (France) Merck Serono, Epfl Innovation Park, Lausanne (Switzerland) Université de Sao Paolo / Centre d’oncologie à l’hopital de Sírio Libanês, (Brazil) University of Leuven, Leuven (Belgium) F. Hoffmann-La Roche Ltd., Pharma, Ba
  • Purpose Purpose We developed a drug-disease simulation model to predict antitumor response and overall survival in phase III studies from longitudinal tumor size data in phase II trials. Methods We developed a longitudinal exposure-response tumor-growth inhibition (TGI) model of drug effect (and resistance) using phase II data of capecitabine (n  34) and historical phase III data of fluorouracil (FU; n  252) in colorectal cancer (CRC); and we developed a parametric survival model that related change in tumor size and patient characteristics to survival time using historical phase III data (n  245). The models were validated in simulation of antitumor response and survival in an independent phase III study (n  1,000 replicates) of capecitabine versus FU in CRC. Results The TGI model provided a good fit of longitudinal tumor size data. A lognormal distribution best described the survival time, and baseline tumor size and change in tumor size from baseline at week 7 were predictors (P  .00001). Predicted change of tumor size and survival time distributions in the phase III study for both capecitabine and FU were consistent with observed values, for example, 431 days (90% prediction interval, 362 to 514 days) versus 401 days observed for survival in the capecitabine arm. A modest survival improvement of 39 days (90% prediction interval, 21 to 110 days) versus 35 days observed was predicted for capecitabine. Conclusion The modeling framework successfully predicted survival in a phase III trial on the basis of capecitabine phase II data in CRC. It is a useful tool to support end-of-phase II decisions and design of phase III studies.
Nadia Terranova, Kheizurane_ElMekki
Annotations have not been checked.
This model is not certified.
  • Model owner: Nadia Terranova
  • Submitted: Dec 11, 2015 5:10:41 PM
  • Last Modified: Jul 13, 2016 12:25:08 PM
Revisions
  • Version: 25 public model Download this version
    • Submitted on: Jul 13, 2016 12:25:08 PM
    • Submitted by: Nadia Terranova
    • With comment: Updated model annotations.
  • Version: 21 public model Download this version
    • Submitted on: Jul 13, 2016 12:13:22 PM
    • Submitted by: Nadia Terranova
    • With comment: Updated model annotations.
  • Version: 19 public model Download this version
    • Submitted on: Jul 12, 2016 2:40:25 PM
    • Submitted by: Kheizurane_ElMekki
    • With comment: Updated model annotations.
  • Version: 14 public model Download this version
    • Submitted on: Jun 3, 2016 2:04:23 PM
    • Submitted by: Kheizurane_ElMekki
    • With comment: Updated model annotations.
  • Version: 8 public model Download this version
    • Submitted on: Dec 11, 2015 5:10:41 PM
    • Submitted by: Nadia Terranova
    • With comment: Edited model metadata online.
 
Help